A major new collaborative effort, the Global Breast Cancer Initiative, is being introduced today by the World Health Organization, with the objective of reducing global breast cancer mortality by 2.5% per year until 2040, thereby averting an estimated 2.5 million deaths. In recognition of International Women’s Day, WHO is hosting an adv
Bluebird: CAR T cell therapy approval puts us on the road to broader oncology success The FDA’s recent endorsement of Abecma marks the first approved treatment in oncology for gene therapy developer, bluebird bio.
On March 26, the US Food and Drug Administration (FDA) approved Abecma [idecabtagene vicleucel; ide-cel] as the first B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy for patients with relapsed or refractory multiple myeloma.
The therapy is being jointly developed and commercialized in the US as part of a co-development, co-promotion, and profit share deal between Bristol Myers Squibb (BMS) and bluebird bio.
(0)
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 01, 2021(NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announces that Ares Trading S.A., an affiliate of Merck KGaA, Darmstadt, Germany has exercised its option to develop an additional bispecific program under the ongoing collaboration with F-star.
This is the third option to license a preclinical program that Merck KGaA, Darmstadt, Germany has exercised in the ongoing collaboration with F-star. Merck KGaA, Darmstadt, Germany and F-star originally entered into a collaboration agreement in 2019 with the first option to license. In July 2020, Merck KGaA, Darmstadt, Germany brought the second program from the collaboration into its pipeline, and today has exercised its third option, taking over future development and commercialization of the program. An undisclosed option exercise payment will be
Ajinomoto and Bright Peak partner to develop immunocytokines Ajinomoto Co., Inc, and Bright Peak Therapeutics Inc. have entered into a research collaboration and license agreement to develop immunocytokines.
Basel, Switzerland based, Bright Peak, is a biotechnology company developing next generation immunotherapies for cancer and autoimmune disease. The deal sees it incorporate AJICAP, Ajinomoto Co.’s proprietary site-specific bioconjugation technology, for the development of Bright Peak immunocytokines.
The companies outlined that there is potential for the combination of antibodies with Bright Peak s cytokine derivatives conjugated by AJICAP to target wide range of oncology applications, the technology may be harnessed to provide a clinical benefit to patients.
Sarah Harding was nervous about reuniting with her Girls Aloud bandmates.
The 39-year-old singer admits she was so racked with nerves before she met up with her fellow Sound of the Underground hitmakers - Cheryl Tweedy, Nicola Roberts, Kimberley Walsh and Nadine Coyle - amid her cancer battle as she was worried they would all turn up looking fabulous and glamorous and she felt she wasn t.
She shared: I was so happy when Peter [Loraine] suggested organising a couple of days away so that all of us could be together. I guess you could call it a Girls Aloud reunion. The plan was for us to go to Soho Farmhouse . I did have my reservations and fears about the reunion get-together, though. It was going to be the first time weâd all seen one another in about eight years. That in itself was nerve-wracking enough, but the fact that I felt and looked the way I did made it worse . The steroids Iâd been taking made me look bloated, and Iâd lost my eyelashes due to the chem